A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Condition:   Advanced Solid Tumors Cancer Interventions:   Drug: ABBV-368;   Drug: Tilsotolimod;   Drug: Nab-paclitaxel;   Drug: ABBV-181 Sponsors:   AbbVie;   Idera Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials